Management of end stage cardiac failure

Postgraduate Medical Journal

Volumn 83, Issue 980, 2007, Pages 395-401

  Johnson, Miriam J ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CLINICAL FEATURE; DYSPNEA; FATIGUE; FINANCIAL MANAGEMENT; HEALTH CARE; HEART FAILURE; HUMAN; MORBIDITY; MORTALITY; NAUSEA AND VOMITING; PAIN; PALLIATIVE THERAPY; PROGNOSIS; REVIEW; SOCIAL ASPECT;

DYSPNEA; FATIGUE; HEALTH SERVICES ACCESSIBILITY; HEART FAILURE, CONGESTIVE; HUMANS; PAIN; PALLIATIVE CARE; PATIENT CARE PLANNING; PROGNOSIS; RESUSCITATION ORDERS; TERMINAL CARE; TERMINALLY ILL;

EID: 34250765357     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2006.055723     Document Type: Review

References (76)

1. Murray SA, Boyd K, Kendall M, et al. Dying of lung cancer or cardiac failure: prospective qualitative interview study of patients and their carers in the community. BMJ 2002;235:929-34.
2. Anderson H, Ward C, Eardley A, et al. The concerns of patients under palliative care and a heart failure clinic are not being met. Palliative Med 2001;15:279-86.
3. Levenson JW, McCarthy EP, Lynn J, et al. The last six months of life for patients with congestive heart failure. J Am Geriatr Soc 2000;48(5 suppl):S101-9.
4. Nordgren L, Sorensen S. Symptoms experienced in the last six months of life with end-stage heart failure. Eur J Cardiovasc Nurs 2003;2:213-7.
5. Hobbs FD, Kenkre JE, Roalfe AK, et al. A cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur Heart J 2002;23:1867-76.
6. Buetow SA, Coster G. Do general practice patients with heart failure understand its nature and seriousness, and want improved information? Patient Educ Couns 2001;45:181-5.
7. Rogers A, Addington-Hall JM, McCoy AS, et al. A qualitative study of chronic heart failure patients' understanding of their symptoms and drug therapy. Eur J Heart Fail 2002;4:283-7.
8. McKinley RK, Stokes T, Exley C, et al. Care of people dying with malignant and cardio-respiratory disease in general practice. Br J Gen Pract 2004;54:909-13.
9. Department of Health. National Service Framework for coronary heart disease - modern standards and service models. London: Department of Health, 2000.
10. National Institute for Health and Clinical Excellence. Management of chronic heart failure in adults in primary and secondary care. London: NICE, 2003.
11. Department of Health. Developing services for heart failure. London: Department of Health, 2003.
12. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced ejection fractions. N Engl J Med 1992;327:685-91.
13. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
14. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe heart failure. N Engl J Med 1987;316:1429-35.
15. The Acute Infarction Ramipril Efficiency (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
16. Granger CB, McMurray JJV, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-6.
17. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.
18. Cohn JN, Tognoni G for the Valsartan Heart Failure Trial Investigators. A randomised trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
19. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
20. Pitt B, Remme WJ, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
21. CIBIS II Investigators. The cardiac insufficiency bisoprolol study II (CIBIS II): a randomised trial. Lancet 1999;353:9-13.
22. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
23. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001-9.
24. Cleland JF, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronisation on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539-49.
25. Moss AJ, Hall WJ, Cannon DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996;335:1933-40.
26. Clark AL, McDonagh T. The origin of symptoms in chronic heart failure. Heart 1997;78:429-30.
27. Moore DP, Weston AR, Hughes JM, et al. Effects of increased inspired oxygen concentrations on exercise performance in chronic heart failure. Lancet 1992;339:850-3.
28. Resfrick LJ, Davies SW, Noone L, et al. Ambulatory oxygen in chronic heart failure. Lancet 1992;340:1192-3.
29. Russell SD, Koshkarian GM, Medinger AE, et al. Lack of effect of increased inspired oxygen concentrations on maximal exercise capacity or ventilation in stable heart failure. Am J Cardiol 1999;84:1412- 16.
30. Booth S, Wade R, Johnson MJ, et al. The use of oxygen in the palliation of breathlessness. A report of the Expert Working Group of the Scientific Committee of the Association of Palliative Medicine. Resp Med 2004;98:66-77.
31. Moore S, Corner J, Haviland J, et al. Nurse led follow up and conventional medical follow up in management of patients with lung cancer: randomised trial [erratum: BMJ 2002;325:1386]. BMJ 2002;325:1145.
32. Schwartzstein RM, Lahive K, Pope A, et al. Cold facial stimulation reduces breathlessness induced in normal subjects. Am Rev Respir Dis 1987;136:58-61.
33. Williams SG, Wright DJ, Diesch JP, et al. Effect of low dose diamorphine on exercise capacity in patients with chronic heart failure. Heart 2001;85(Suppl 1):4.
34. Chua TP, Harrington D, Ponikowski P, et al. Effects of dihydrocodeine on chemosensivity and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 1997;29:147-52.
35. Johnson MJ, McDonagh TA, Harkness A, et al. Morphine for the relief of breathlessness in patients with chronic heart failure - a pilot study. Eur J Heart Failure 2002;4:753-6.
36. Farncombe M, Chater S. Case studies outlining use of nebulised morphine for patients with end-stage chronic lung and cardiac disease. J Pain Symptom Manage 1993;8:221-5.
37. World Health Organization. Cancer pain relief, 2nd ed. Geneva: World Health Organization, 1996:74.
38. Bueno EA, Mamtani R, Frishman WH. Alternative approaches to the medical management of angina pectoris: acupuncture, electrical nerve stimulation, and spinal cord stimulation. Heart Dis 2001;3:236-41.
39. Borjesson M, Eriksson P, Dellborg M, et al. Transcutaneous electrical nerve stimulation in unstable angina pectoris. Coronary Artery Disease 1997;8:543-50.
40. Mannheimer C, Emanuelsson H, Waagstein F. The effect of transcutaneous electrical nerve stimulation (TENS) on catecholamine metabolism during pacing-induced angina pectoris and the influence of naloxone. Pain 1990;41:27-34.
41. DeJongste MJL, Hautvast RWM, Hillege JL, Lie KI on behalf of the Working Group on Neurocardiology. Efficacy of spinal cord stimulation as adjuvant therapy for intractable angina pectoris. J Am Coll Cardiol 1994;23:1592-7.
42. Sanderson JE, Brooksby P, Waterhouse D, et al. Epidural spinal electrical stimulation for severe angina: a study of its effect on symptoms, exercise tolerance, and degree of ischaemia. Eur Heart J 1992;13:628-33.
43. Mannheimer C, Eliasson T, Augustinsson L-E, et al. Electrical stimulation versus coronary artery bypass surgery in severe angina pectoris. The ESBY study. Circulation 1998;97:1157-63.
44. Heerdink E, Leufkens H, Herings R, et al. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics Arch Intern Med 1998;158:1108-12.
45. Ponikowski P, Anker SD, Chua TP, et al. Oscillatory breathing patterns during wakefulness in patients with chronic heart failure: clinical implications and role of augmented peripheral chemosensitivity. Circulation 1999;100:2418-24.
46. Tan LB, Bryant S, Murray RG. Detrimental haemodynamic effects of cyclizine in heart failure. Lancet, 1988;i, 560-1.
47. Pasini E, Opasich C, Pastoris O, et al. Inadequate nutritional intake far daily life activity of clinically stable patients with chronic heart failure. Am J Cardiol 2004;93:41A-43A.
48. Anker SD, Sharma R. The syndrome of cardiac cachexia. Int J Cardiol 2002;85:51-66.
49. Davis MP, Frandsen JL, Walsh D, et al. Mirtazepine for pruritis. J Pain Symptom Manage 2003;25:288-91.
50. Balaskas EV, Bamihas GI, Karamouzis M, et al. Histamine and serotonin in uraemic pruritis: effect of ondansetron in CAPD - pruritic patients. Nephron 1998;78:395-402.
51. Murphy M, Reaich D, Pai P, et al. A randomised, placebo-controlled, double-blind trial of ondansetron in renal itch. Br J Dermatol 2003;148:314-7.
52. Silva SR, Viana PC, Lugon NV, et al. Thalidomide for the treatment of uraemic pruritis; a cross over, randomised, double blind trial. Nephron 1994;67:270-3.
53. Murberg TA, Bru E, Svebak S, et al. Depressed mood and subjective health symptoms as predictors of mortality in patients with congestive heart failure: a two-years follow up study. Int J Psychiatr Med 1999;29:311-26.
54. Guck TP, Elsasser GN, Kavan MG, et al. Depression and congestive heart failure. Congestive Heart Failure 2003;9:163-9.
55. Alvarez W Jr, Pickworth KK. Safety of anti-depressant drugs in the patient with cardiac disease: a review of the literature. Pharmacotber 2003;23:754-71.
56. Luskin F, Reitz M, Newll K, et al. A controlled pilot study of stress management training of elderly patients with congestive heart failure. Prev Cardiol 2002;5:168-72.
57. Koukouvou G, Kouidi E, Iacovides A, et al. Quality of life, psychological and physiological changes following exercise training in patients with chronic heart failure. J Rehab Med 2004;36:36-41.
58. Cheshire & Merseyside Cardiac Network (CMCN) Website. http://www.cmcn.nhs.uk.
59. Free A. Extending the GSF to non cancer patients. July 2005. Link from http://www.goldstandardsframework.nhs.uk/non_cancer.php.
60. Anon. Coronary Heart Disease Collaborative Supportive and Palliative Care for Advanced Heart Failure 2005. www.modern.nhs.uk/chd.
61. Liverpool Care Pathway for the Dying. www.lcp-mariecurie.org.uk.
62. Mueller PS, Hook CC, Hayes DI. Ethical analysis of withdrawal of pacemaker or implantable cardioverter-defibrillator support at the end of life. Mayo Clin Pract 2003;78:959-63.
63. Ross HM. Deactivating implantable cardioverter defibrillators/in response. Ann Intern Med 2005;143:690.
64. Berger JT. Deactivating implantable cardioverter defibrillators/in response. Ann Intern Med 2005;143:691.
65. Verma AK, da Silva JH, Kuhl DR. Diuretic effects of subcutaneous furosemide in human volunteers: a randomised pilot study. Ann Pharmacother 2004;38:544-9.
66. Goenaga MA. Millet M, Sanchez E, et al. Subcutaneous furosemide. Ann Pharmacother 2004;38:1751.
67. Gannon C. Palliative care in terminal cardiac failure; hospices cannot fulfil such a vast and diverse role BMJ 1995;310:310-11.
68. Beattie JM, Murray RG, Brittle J, et al. Palliative care in terminal cardiac failure. Small numbers of patients with terminal cardiac failure may make considerable demands on services. BMJ 1995;310:1411.
69. Davidson PM, Paull G, Introna K, et al. Integrated, collaborative palliative care in heart failure: the St George Heart Failure Service experience 1999-2002. J Cardiovascular Nursing 2004;19:68-75.
70. Johnson MJ, Houghton T. Palliative care for patients with heart failure: description of a service. Palliat Med 2006;20:211-14.
71. Daley A, Matthews C, Williams A. Heart failure and palliative care services working in partnership: report of a new model of care. Palliat Med 2006;20:593-601.
72. Dharmasena HP, Forbes K. Palliative care for patients with non-malignant disease: will hospital physicians refer? Palliat Med 2001;15:412-81.
73. Sykes J, Chester T. Palliative care far chronic heart failure patients. Heart 2003;89(Suppl 1):A8(018).
74. Paes P. A pilot study to assess the effectiveness of a palliative care clinic in improving the quality of life for patients with severe heart failure. Palliat Med 2005;19:505-6.
75. Gibbs LME, Khatri AK, Gibbs JSR. Survey of specialist palliative care and heart failure: September 2004. Palliat Med 2006;20:603-9.
76. Supportive and Palliative Care in Heart Failure: a resource kit for cardiac networks. Heart Improvement Programme. www.heart.nhs.uk Available fromNHS Health Improvement Programme 3rd floor, St.John's House, East Street.Leicester LE1 6NB..